ATE443070T1 - Metallkomplexe mit vitamin b12 als ligand - Google Patents

Metallkomplexe mit vitamin b12 als ligand

Info

Publication number
ATE443070T1
ATE443070T1 AT05706857T AT05706857T ATE443070T1 AT E443070 T1 ATE443070 T1 AT E443070T1 AT 05706857 T AT05706857 T AT 05706857T AT 05706857 T AT05706857 T AT 05706857T AT E443070 T1 ATE443070 T1 AT E443070T1
Authority
AT
Austria
Prior art keywords
vitamin
ligand
metal complexes
cyanide
complex
Prior art date
Application number
AT05706857T
Other languages
English (en)
Inventor
Roger Alberto
Castro Hector Knight
Stefan Mundwiler
Susanne Kunze
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE443070T1 publication Critical patent/ATE443070T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
AT05706857T 2004-01-08 2005-01-10 Metallkomplexe mit vitamin b12 als ligand ATE443070T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04075003 2004-01-08
EP04077937 2004-10-25
PCT/EP2005/000168 WO2005068483A1 (en) 2004-01-08 2005-01-10 Metal complexes having vitamin b12 as a ligand

Publications (1)

Publication Number Publication Date
ATE443070T1 true ATE443070T1 (de) 2009-10-15

Family

ID=34796701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05706857T ATE443070T1 (de) 2004-01-08 2005-01-10 Metallkomplexe mit vitamin b12 als ligand

Country Status (12)

Country Link
US (1) US7692002B2 (de)
EP (1) EP1704157B1 (de)
JP (1) JP2007518727A (de)
KR (1) KR20070010119A (de)
AT (1) ATE443070T1 (de)
AU (1) AU2005205126A1 (de)
BR (1) BRPI0506740A (de)
CA (1) CA2552916C (de)
DE (1) DE602005016648D1 (de)
ES (1) ES2334923T3 (de)
IL (1) IL176664A (de)
WO (1) WO2005068483A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101019555B (zh) * 2007-03-23 2011-03-30 南京师范大学 稀土-氨基酸-维生素三元配合物植物生长调节剂及其制备方法
US9512156B2 (en) * 2010-03-08 2016-12-06 University Of Zurich Carbon monoxide releasing rhenium compounds for medical use
BR112013010487B1 (pt) 2010-11-02 2021-02-02 Promega Corporation compostos de coelenterazina, kit compreendendo ditos compostos e método para detectar luminescência em uma amostra in vitro
WO2012061477A1 (en) 2010-11-02 2012-05-10 Promega Corporation Coelenterazine derivatives and methods of using same
US9385033B2 (en) * 2013-09-27 2016-07-05 Intel Corporation Method of forming a metal from a cobalt metal precursor
US9927430B2 (en) 2014-01-29 2018-03-27 Promega Corporation Pro-substrates for live cell applications
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560782A (en) 1982-11-19 1985-12-24 Research Corporation Anti-tumor diplatinum coordination compounds
US4673631A (en) * 1984-12-15 1987-06-16 Canon Kabushiki Kaisha Toner, charge-imparting material and composition containing metal complex
WO1989010772A2 (en) * 1988-05-09 1989-11-16 The Public Health Laboratory Service Board Use of metal chelate complexes in dehalogenation
US5393909A (en) * 1988-11-22 1995-02-28 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
GB8910760D0 (en) * 1989-05-10 1989-06-28 Health Lab Service Board Corrin mediated degradation of organic nitrogen compounds
DE19712388A1 (de) 1997-03-25 1998-10-01 Studiengesellschaft Kohle Mbh Verfahren zur Synthese von aromatisch substituierten Olefinen
US6844425B1 (en) * 1999-02-24 2005-01-18 Mallinckrodt Inc. Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy
US6797521B2 (en) 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
US6180087B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Tunable indocyanine dyes for biomedical applications
US6180085B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Dyes
EP2289508A1 (de) * 2001-01-30 2011-03-02 Dainippon Sumitomo Pharma Co., Ltd. Kombinierte Behandlung für Lungenkrebs
DE60326465D1 (de) * 2002-09-03 2009-04-16 Univ Zuerich Herstellung von m(co)3-komplexen durch festphasentechniken durch metal-unterstützte trennung vom festen träger

Also Published As

Publication number Publication date
US7692002B2 (en) 2010-04-06
EP1704157B1 (de) 2009-09-16
ES2334923T3 (es) 2010-03-17
IL176664A0 (en) 2006-10-31
JP2007518727A (ja) 2007-07-12
US20090175775A1 (en) 2009-07-09
BRPI0506740A (pt) 2007-05-15
KR20070010119A (ko) 2007-01-22
AU2005205126A1 (en) 2005-07-28
DE602005016648D1 (de) 2009-10-29
IL176664A (en) 2013-05-30
CA2552916A1 (en) 2005-07-28
WO2005068483A1 (en) 2005-07-28
EP1704157A1 (de) 2006-09-27
CA2552916C (en) 2014-11-18

Similar Documents

Publication Publication Date Title
Blackman The coordination chemistry of tripodal tetraamine ligands
Casas et al. A gold (I) complex with a vitamin K3 derivative: characterization and antitumoral activity
MX2008011107A (es) Catalizadores de metal de transicion fluorados y formacion de los mismos.
TW200633976A (en) Organic silver complexes, their preparation methods and their methods for forming thin layers
Parmar et al. Iron catalysed cross-couplings of azetidines–application to the formal synthesis of a pharmacologically active molecule
NO20035597L (no) Forbedrede chelator-konjugater
ATE443070T1 (de) Metallkomplexe mit vitamin b12 als ligand
NZ592400A (en) Transition metal complexes of bis[thiohydrazide amide] compounds
Chakraborty et al. Mononuclear and heterometallic dinuclear, trinuclear and dimer-of-dinuclear complexes derived from single-and double-compartment Schiff base ligands having a less utilized diamine
TW200720399A (en) Light-emitting element and iridium complex
TW200634128A (en) Polymer compound and elements using the same
WO2005001415A3 (en) Optically pure and enriched isomers of chelating ligands and contrast agents
EP1775289A4 (de) Neue imidazolidinderivate
Jang et al. Synthesis and crystal structures of Mn (II), Co (II), Ni (II), Cu (II), and Zn (II) metal complexes with NNO functionalized ligands
UA87561C2 (ru) Способ получения замещенных бифенилов
EP1706452A4 (de) Aromatische triamid-lanthanid-komplexe
TW200611689A (en) Cancer chemotherapy
WO2009010129A8 (de) Bispidonliganden und deren metallkomplexe
Ye et al. Synthesis and in vitro cytotoxicity of novel lipophilic (diamine) platinum (II) complexes of salicylate derivatives
IL174642A0 (en) A process for the preparation of adapalene
TW200728315A (en) Phosphorus transition-metal complex, method of producing the same, and anticancer agent forming the same
ATE471513T1 (de) Neue chemilumineszenzverbindungen und ihre verwendung
NO20055334L (no) Bifunksjonelle tridentate pyrazolylinneholdende ligander for RE og TC trikarbonylkomplekser
Shakir et al. Synthesis of 14‐Membered Pentaazabis (Macrocyclic) Complexes of Co (II), Ni (II), Cu (II), and Zn (II) Derived from Hydrazine and Their Physico‐chemical Studies
WO2005108408A3 (en) Process for the racemoselective preparation of ansa-metallocenes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties